Logo image of FBRX

FORTE BIOSCIENCES INC (FBRX) Stock Fundamental Analysis

NASDAQ:FBRX - Nasdaq - US34962G2084 - Common Stock - Currency: USD

11.75  -0.16 (-1.34%)

After market: 11.75 0 (0%)

Fundamental Rating

2

Taking everything into account, FBRX scores 2 out of 10 in our fundamental rating. FBRX was compared to 549 industry peers in the Biotechnology industry. FBRX has a great financial health rating, but its profitability evaluates not so good. FBRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FBRX had negative earnings in the past year.
FBRX had a negative operating cash flow in the past year.
FBRX had negative earnings in each of the past 5 years.
FBRX had a negative operating cash flow in each of the past 5 years.
FBRX Yearly Net Income VS EBIT VS OCF VS FCFFBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of FBRX (-93.14%) is worse than 74.32% of its industry peers.
FBRX has a Return On Equity (-115.03%) which is in line with its industry peers.
Industry RankSector Rank
ROA -93.14%
ROE -115.03%
ROIC N/A
ROA(3y)-56.48%
ROA(5y)-59.11%
ROE(3y)-63.42%
ROE(5y)-64.27%
ROIC(3y)N/A
ROIC(5y)N/A
FBRX Yearly ROA, ROE, ROICFBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FBRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FBRX Yearly Profit, Operating, Gross MarginsFBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for FBRX has been increased compared to 1 year ago.
Compared to 5 years ago, FBRX has more shares outstanding
There is no outstanding debt for FBRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FBRX Yearly Shares OutstandingFBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FBRX Yearly Total Debt VS Total AssetsFBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.53 indicates that FBRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
FBRX's Altman-Z score of 2.53 is fine compared to the rest of the industry. FBRX outperforms 71.77% of its industry peers.
There is no outstanding debt for FBRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.53
ROIC/WACCN/A
WACCN/A
FBRX Yearly LT Debt VS Equity VS FCFFBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 5.22 indicates that FBRX has no problem at all paying its short term obligations.
FBRX has a Current ratio (5.22) which is comparable to the rest of the industry.
A Quick Ratio of 5.22 indicates that FBRX has no problem at all paying its short term obligations.
The Quick ratio of FBRX (5.22) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.22
Quick Ratio 5.22
FBRX Yearly Current Assets VS Current LiabilitesFBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.48% over the past year.
EPS 1Y (TTM)40.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

FBRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.49% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.67%
EPS Next 2Y33.87%
EPS Next 3Y22.17%
EPS Next 5Y11.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FBRX Yearly Revenue VS EstimatesFBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2028 2029 2030 2031 2032 100M 200M 300M 400M
FBRX Yearly EPS VS EstimatesFBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

FBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FBRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBRX Price Earnings VS Forward Price EarningsFBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBRX Per share dataFBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

FBRX's earnings are expected to grow with 22.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.87%
EPS Next 3Y22.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTE BIOSCIENCES INC

NASDAQ:FBRX (8/19/2025, 8:00:02 PM)

After market: 11.75 0 (0%)

11.75

-0.16 (-1.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners87.23%
Inst Owner Change94.47%
Ins Owners1.86%
Ins Owner Change0.55%
Market Cap146.05M
Analysts82.22
Price Target60.18 (412.17%)
Short Float %2.74%
Short Ratio1.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.42%
Min EPS beat(2)-41.38%
Max EPS beat(2)26.55%
EPS beat(4)2
Avg EPS beat(4)-9.03%
Min EPS beat(4)-58.82%
Max EPS beat(4)37.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)14.15%
EPS NQ rev (3m)0.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-34.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 3.8
EV/EBITDA N/A
EPS(TTM)-9.32
EYN/A
EPS(NY)-3.69
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.77
OCFYN/A
SpS0
BVpS3.09
TBVpS3.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.14%
ROE -115.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.48%
ROA(5y)-59.11%
ROE(3y)-63.42%
ROE(5y)-64.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 209.52%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.22
Quick Ratio 5.22
Altman-Z 2.53
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.78%
EPS Next Y71.67%
EPS Next 2Y33.87%
EPS Next 3Y22.17%
EPS Next 5Y11.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-202.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-201.75%
OCF growth 3YN/A
OCF growth 5YN/A